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MicroRNAs (miRNAs) were first described in 1993 1-2, formally classified in the early 2000’s 3 and 14 
have been at the forefront of cell physiology research for the last two decades. In humans, at least 61 15 
tissues express over 1900 miRNAs (https://asia.ensembl.org/Homo_sapiens/Info/Annotation) with 16 
some level of tissue-specificity 4. MiRNAs primarily, 5 but not exclusively 6, act by repressing a target 17 
mRNA molecule and the translation of the corresponding protein. Most functional miRNA/mRNA 18 
interactions are governed by base complementarity principles, but the scientific community is only 19 
starting to appreciate the complexity of miRNA targeting rules 7 and the full extent of their influence 20 
on gene expression.  21 
MiRNAs are not only present in tissues. Biological fluids, including whole blood, plasma and serum, 22 
as well as breast milk, cerebrospinal fluid, saliva and urine, all contain extracellular, or circulating “cell 23 
free” miRNAs (cf-miRs) that are secreted by cells8. Cf-miRs were soon identified as potential 24 
biomarkers for a range of physiological and pathophysiological conditions and have since received 25 
growing attention. The popularity of cf-miRs is two-fold: the reasonable ease of access to most 26 
extracellular fluids, and the discovery of high levels of regulation of specific cf-miRs in the presence of 27 
diseases 4, 8-10. These include cancer 11, cardiovascular disease 12 and liver disease 13, but also exercise 28 
14, making cf-miRs promising biomarkers. As such, miRNAs have not only instigated a rare paradigm 29 
shift in the way we study gene regulation, but have also allowed access to a novel, non-invasive marker 30 
of human health 15. In April 2020, a PubMed search using the terms “human” and “microRNA” or 31 
“miRNA” returned over 100,000 articles. When refined to add the term “circulating”, the same search 32 
returned close to 3500 articles, all published in the last decade.  33 
Cf-miRs are found in circulation in two distinct forms, “vesicular” cf-miRs (miRNAs that are contained 34 
in extracellular vesicles such as exosomes, microvesicles or apoptotic bodies) or “non-vesicular” cf-35 
miRs (miRNAs that are free in circulation as part of RNA-binding protein complexes). The presence of 36 
non-vesicular miRNAs in circulation may result from active export systems and/or passive leakage 37 
through the plasma membrane following cell damage or death 16. However, their biological function 38 
and how they are protected from RNase degradation remain poorly characterised 17. Some evidence 39 
suggests that non-vesicular cf-miRs are protected by forming RNA-binding protein complexes, 40 
including nucleophosmin-1 (NPM1) in vitro 18 and Argonaute2 (AGO2) in vivo 16, 19. The conditions in 41 
which tissues selectively secrete vesicular and non-vesicular miRNAs into the circulation and their 42 
subsequent uptake by recipient cells are not fully understood. However, a number of recent studies 43 
indicate that they are tightly-regulated and highly selective process 20-22 that play a functionally 44 
important role in cross-tissue communication 20, 23.  45 
Accessing vesicular cf-miRs relies on complex extraction and sorting techniques 24-26. In contrast, the 46 
first step of the classical RNA isolation process lyses extracellular vesicles, leading to the extraction of 47 
both vesicular and non-vesicular cf-miRs. For this reason, the majority of the literature to date has 48 
focused on the whole cf-miR pool without attempting to discriminate between the two fractions. There 49 
are however significant differences in the miRNA profile of the vesicular and non-vesicular pool 27-28, 50 
possibly owing to selective loading of miRNAs into extracellular vesicles 21, 29. However, early limited 51 
evidence suggest that in plasma, most cf-miRs may not be associated with exosomes/microvesicles 19. 52 
Distinguishing between the two different cf-miR forms may therefore be essential to understand their 53 
specific physiological function and improve biomarker sensitivity 16.  54 
A series of molecular techniques are used to measure the expression of miRNAs from tissues and fluids 55 
(Figure 1). Single miRNA expression is usually assessed using primer-based real time PCR, while 56 
miRNA arrays and small RNA sequencing have the potential to profile the expression of hundreds of 57 
miRNAs simultaneously. Reflecting the more general trend in cf-miR research, in our field of exercise 58 
physiology, only 10 studies to date have focused on vesicular cf-miRs, with the vast majority of studies 59 
investigating the whole cf-miR pool. Regrettably, it is not uncommon to observe important 60 
discrepancies in cf-miR expression and regulation between these studies 30. Differences in analytical 61 
techniques, research protocols and participant characteristics account for some of these differences. 62 
However, a number of methodological factors that are not unique to the exercise field have been broadly 63 
overlooked in cf-miR research. 64 
Most studies have been performed in whole blood, serum and plasma, and it is important to 65 
acknowledge that blood cells either contain 31 or produce 32 their own miRNAs. Differences in blood 66 
cell number therefore constitute a confounding factor when assessing changes in the cf-miR pool. Using 67 
cell-free plasma and serum may bypass this issue, pending that haemolysis is strictly controlled at 68 
collection as well as in the final extract 33. In addition, platelet-derived miRNA contamination is 69 
frequent in archived plasma and serum samples, and residual platelets should be thoroughly eliminated 70 
prior to 34 or after 35 freezing to ensure accurate results. Another challenge intrinsic to cf-miR detection 71 
resides in the low starting RNA amounts, owing to miRNA dilution and limited sample availability. In 72 
most cases, RNA concentration is too low to be reliably measured. As a result, most studies use the 73 
RNA extracted from an equal amount of fluid without formal quantification. This approach is valid but 74 
contingent to the use of strict analytical controls at each stage of the downstream process. For PCR 75 
based studies, Nielsen et al. have proposed a stringent workflow including several synthetic spike-in 76 
controls during the extraction, reverse-transcription and amplification processes to account for potential 77 
differences in starting RNA amounts 33. Although integral to the reliability and reproducibility of the 78 
results, these quality control steps are time consuming, cost generating and have not been systematically 79 
implemented 30. Lastly, while high-throughput technologies come with global normalization strategies, 80 
normalization of single cf-miR expression must be carefully considered. There is a lack of reliable 81 
housekeeping miRNAs, and single-strand DNA quantification is hardly possible due to low starting 82 
RNA concentrations 36. Software using the most stable miRNAs from a given panel to compute a 83 
normalization factor are therefore warranted when no other option is available. Numerous studies, 84 
especially recent ones33, 37-39 , have successfully implemented a combination of these quality control 85 
steps. However, the bulk of published studies may still rely on inaccurate approaches that compromise 86 
the reliability of the results and risk misinforming the field. A final consideration intrinsic to human 87 
physiology research resides in striking the right balance between participant burden and appropriate 88 
statistical power. Ethical considerations combined with financial constraints as well as the very nature 89 
of exploratory research have led to the publication of numerous underpowered studies. It is important 90 
to bear in mind that, because large effect sizes are rare in physiological sciences, significant findings 91 
based on small sample sizes are more likely to constitute false-positives42. This remains a significant 92 
barrier for implementation of fundamental results into clinical settings. There is now sufficient 93 
published research in the field to estimate appropriate effect sizes, and researchers should take 94 
advantage of the non-invasive nature of cf-miRs research to aim for larger sample sizes. An effort 95 
should also be made to interpret new findings in the light of a pragmatic combination of statistical 96 
significance, physiological relevance and the existing literature.  97 
In conclusion, cf-miRs are attractive potential biomarkers that are readily available as they do not rely 98 
on invasive tissue sampling. The apparent simplicity and specificity of the approach has led to the rapid 99 
development of a considerable body of research. Measuring cf-miR expression levels however presents 100 
unique challenges that have been frequently overlooked. Unless specifically isolating extracellular 101 
vesicles, their cargo becomes part of the cf-miR pool. Vesicular and non-vesicular cf-miRs may 102 
however have different physiological relevance and role in tissue cross-talk. Secondly, a majority of 103 
published studies have failed to put the relevant quality controls in place, leading to significant 104 
discrepancies and a lack or reproducibility in the field. Finally, our functional knowledge is limited and 105 
more research is warranted to understand the biological principles underlying the release and uptake of 106 
both vesicular and non-vesicular cf-miRs. It has been suggested early on that cf-miR research might be 107 
blinded by its own potential 15. It is now our role as researchers to safeguard this important research 108 
field in order to prevent ‘blinded by potential’ becoming ‘wasted potential’.  109 
 110 
Figures 111 
Figure 1. Graphical summary representing non-vesicular and vesicular cell free miRNA (cf-miR) 112 
extraction and analysis techniques including critical quality control (QC) steps. 113 
 114 
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